Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine
Autore:
Clere, G;
Indirizzi:
Ctr Hosp Specialise, Pontorson, France Ctr Hosp Specialise Pontorson France Hosp Specialise, Pontorson, France
Titolo Testata:
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 3, volume: 16, anno: 2001,
pagine: 145 - 151
SICI:
0268-1315(200105)16:3<145:AEATOM>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
MAJOR DEPRESSION; TRICYCLIC ANTIDEPRESSANTS; DRUG; FLUOXETINE;
Keywords:
antidepressant therapy; fluvoxamine; major depression; milnacipran;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Clere, G Care of Tournoux, Inst Rech Pierre Fabre, Dept Rech Clin, 45 Pl Abel Gance, F-92654 Boulogne, France Care of Tournoux 45 Pl Abel Gance Boulogne France F-92654 France
Citazione:
G. Clere, "Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine", INT CLIN PS, 16(3), 2001, pp. 145-151

Abstract

The antidepressant efficacy and tolerability of milnacipran, a dual actionserotonin-noradrenaline reuptake inhibitor, were compared with those of the selective serotonin reuptake inhibitor, fluvoxamine, in 113 patients withmoderate to severe major depression. Treatment with milnacipran, 50 mg b.d. for 6 weeks, produced a significantly greater reduction in Montgomery-Asberg Depression Rating Scale (MADRS) scores than fluvoxamine, 100 mg b.d. (P= 0.007; 65.4% versus 49.9%, respectively); significantly greater decreases were also seen on days 7 (P = 0.04) and 28 (P = 0.03), The response rate (the proportion of patients showing a decrease in MADRS scores of at least 50%) was 78.9% in patients receiving milnacipran, compared with 60.7% in fluvoxamine-treated patients (P = 0.04). Milnacipran also produced greater improvements in 24-item Hamilton Depression Rating Scale scores (P = 0.05). On the Clinical Global Impression Improvement scale, 77.2% of milnacipran-treated patients were rated as considerably or markedly improved, compared with 60.7% of patients receiving fluvoxamine (P = 0.06 chi-squared). Both treatments were well tolerated; the only significant difference between the two groups was a higher incidence of tremor and drowsiness in patients treated with fluvoxamine. It is concluded that milnacipran may offer some advantages over selective serotonin reuptake inhibitors, such as fluvoxamine, in the treatment of moderate to severe major depression. Int clin Psychopharmacol 16:135-151 (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/04/20 alle ore 23:01:19